POZEN Inc.  

(Public, NASDAQ:POZN)   Watch this stock  
Find more results for POZN
Feb 5 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 5.49 - 12.69
Open     -
Vol / Avg. 0.00/396,003.00
Mkt cap 194.70M
P/E     -
Div/yield     -
EPS -0.54
Shares 32.78M
Beta 1.60
Inst. own 68%
Mar 7, 2016
Q4 2015 POZEN Inc Earnings Release (Estimated)
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -140.02% 60.74%
Operating margin -140.77% 51.17%
EBITD margin - 51.23%
Return on average assets -72.25% 45.87%
Return on average equity -101.76% 60.98%
Employees 12 -
CDP Score - -


1414 Raleigh Rd Ste 400
CHAPEL HILL, NC 27517-8834
United States - Map
+1-919-9131030 (Phone)
+1-919-9131039 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Aralez Pharmaceuticals Inc., formerly POZEN Inc., is a pharmaceutical company. The Company has entered into a license agreement with Sanofi US, for the commercialization of PA8140 and PA32540, now known as YOSPRALA 81/40 and 325/40 (aspirin / omeprazole delayed release tablets). The Company has developed Treximet in collaboration with GlaxoSmithKline (GSK). Treximet has been approved by the FDA for the acute treatment of migraine attacks with or without aura in adults. The Company has developed VIMOVO with AstraZeneca AB (AstraZeneca). VIMOVO is the brand name for a fixed dose combination of the proton pump inhibitor (PPI) esomeprazole magnesium with the non-steroidal anti-inflammatory drug (NSAID) naproxen in a single tablet. The Company is developing a combination of a PPI and aspirin in a single tablet intended to induce fewer gastrointestinal complications compared to an aspirin taken alone in patients at risk for developing aspirin associated gastric ulcers.